Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Immunotherapy and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CLEC2A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLEC2A ECD-Fc Recombinant Protein High purity (>95%), Endotoxin Controlled (<1 EU/ug). HEK293 Expressed for native glycosylation. Sequence Verified. |
View CLEC2A Products |
| Gene Delivery | CLEC2A Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based binding assays. |
View CLEC2A Products |
| Benchmark Ab | Anti-CLEC2A Recombinant Antibody High-affinity positive control clone for flow cytometry and blocking assays. |
View CLEC2A Products |
| Validator | CLEC2A siRNA Set Target-specific knockdown pool for functional validation in primary cells. |
View CLEC2A Products |
| Related Target A | KLRF1 (NKp80) The primary functional receptor for CLEC2A (KACL) mediating NK cell activation. |
View KLRF1 Products |
| Related Target B | CLEC2D (LLT1) Sybling C-type lectin member modulating NK cell function via the KLRB1 (CD161) pathway. |
View CLEC2D Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining Native Homodimeric Conformation | HEK293 expressed ECD-Fc fusion proteins preserving native dimeric state and glycosylation patterns. |
| Low-Affinity Interaction Detection (CLEC2A-KLRF1) | Avidity-optimized Fc-fusion antigens designed specifically for high-sensitivity SPR/BLI assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CLEC2A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLEC2A therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific NK cell engagers (NKCEs). As first-generation therapies reach the clinic, the next wave of R&D is targeting the modulation of the KACL-NKp80 (CLEC2A-KLRF1) axis to unleash natural killer cell cytotoxicity against refractory hematological malignancies and solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| NK Cell Engagers (NKCE) | Innate Pharma, Affimed | Acute Myeloid Leukemia (AML) | Dual-targeting validation (Need high-purity CLEC2A and KLRF1/NKp80 proteins) |
| Monoclonal Antibodies | Academic Institutes, Biotech Startups | Solid Tumors (Glioblastoma) | Internalization and ADCC assays (Need sequence-verified antigens and benchmark mAbs) |
| Cell Therapy (CAR-NK) | Clinical-stage Immunotherapy Developers | Hematological Malignancies | Target expression verification (Need Lentivirus for stable target cell line construction) |